Oryzon Genomics Future Growth

Future criteria checks 5/6

Oryzon Genomics is forecast to grow earnings and revenue by 61.1% and 59.1% per annum respectively while EPS is expected to grow by 60.3% per annum.

Key information

61.1%

Earnings growth rate

60.3%

EPS growth rate

Biotechs earnings growth	0%
Revenue growth rate	59.1%
Future return on equity	n/a
Analyst coverage	Low
Last updated	25 May 2023

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

BMV:ORY N - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	124	79	N/A	N/A	1
12/31/2024	10	-19	N/A	N/A	2
12/31/2023	6	-7	N/A	N/A	3
3/31/2023	17	-5	N/A	N/A	N/A
12/31/2022	17	-5	-17	-2	N/A
9/30/2022	10	-3	N/A	N/A	N/A
6/30/2022	14	-5	-15	-3	N/A
3/31/2022	12	-5	N/A	N/A	N/A
12/31/2021	12	-5	-18	-4	N/A
9/30/2021	11	-4	N/A	N/A	N/A
6/30/2021	10	-4	-17	-4	N/A
3/31/2021	7	-5	N/A	N/A	N/A
12/31/2020	12	-4	-17	-6	N/A
9/30/2020	12	-4	N/A	N/A	N/A
6/30/2020	13	-4	-16	-4	N/A
3/31/2020	13	-4	N/A	N/A	N/A
12/31/2019	12	-4	-15	-4	N/A
9/30/2019	10	-4	N/A	N/A	N/A
6/30/2019	9	-4	-11	-3	N/A
3/31/2019	8	-2	N/A	N/A	N/A
12/31/2018	8	-1	-9	-1	N/A
9/30/2018	7	-2	N/A	N/A	N/A
6/30/2018	6	-2	-11	-5	N/A
3/31/2018	6	-6	N/A	N/A	N/A
12/31/2017	5	-6	-11	-6	N/A
9/30/2017	6	-6	N/A	N/A	N/A
6/30/2017	6	-6	-10	-4	N/A
3/31/2017	5	-6	N/A	N/A	N/A
12/31/2016	5	-6	N/A	-5	N/A
9/30/2016	6	-5	N/A	N/A	N/A
6/30/2016	6	-4	N/A	-1	N/A
3/31/2016	8	-1	N/A	N/A	N/A
12/31/2015	8	-1	N/A	1	N/A
9/30/2015	8	-1	N/A	N/A	N/A
6/30/2015	7	-1	N/A	N/A	N/A
3/31/2015	11	2	N/A	N/A	N/A
12/31/2014	19	8	N/A	15	N/A
12/31/2013	3	-3	N/A	N/A	N/A
12/31/2012	6	-1	N/A	N/A	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ORY N is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (7.6%).

Earnings vs Market: ORY N is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ORY N is expected to become profitable in the next 3 years.

Revenue vs Market: ORY N's revenue (59.1% per year) is forecast to grow faster than the MX market (6.2% per year).

High Growth Revenue: ORY N's revenue (59.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ORY N's Return on Equity is forecast to be high in 3 years time

Oryzon Genomics Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Recent updates

Oryzon Genomics, S.A. Announces Presentation of Final Data from Portico, Vafidemstat's Global Phase IIb Trial in Borderline Personal Disorder, at the 37th ECNP Annual Conference

Oryzon Genomics S.A. Presents Preliminary Data from Ongoing Phase Ib Frida Trial with Iadademstat Plus Gilteritinib in Relapsed/Refractory Flt3-Mut Aml Patients At Eha-2024

Oryzon Genomics, S.A. Secures Another Important Patent for its Lead CNS Asset, Vafidemstat

ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer

Oryzon Genomics, S.A. Announces Topline Results from Phase IIb Portico Study of Vafidemstat in Borderline Personality Disorder

Oryzon Genomics S.A. announced that it expects to receive €45 million in funding from Nice & Green SA

Oryzon Genomics, S.A. Announces Last Patient Last Visit in Its Phase IIb Portico Study for Borderline Personality Disorder

Oryzon Genomics, S.A. Presents Blinded Aggregated Safety Data from Vafidemstat's Ongoing Phase IIB Portico Trial in Borderline Personal Disorder

Oryzon Genomics, S.A. Reports New Preliminary Blinded Aggregate Safety Data from Its Ongoing Phase IIb Portico Trial

Oryzon Genomics, S.A. Presents Positive Preclinical Data of Ory-4001 for the Treatment of Charcot-Marie-Tooth Disease Presented At the 2023 Peripheral Nerve Society Annual Meeting

Oryzon Genomics, S.A. to Present Positive Preclinical Efficacy Data of ORY-4001 in Charcot-Marie-Tooth (CMT) Disease At the 2023 Peripheral Nerve Society Annual Meeting

Oryzon Genomics S.A. announced that it has received €1.800407 million in funding

ORYZON Announces FDA Clearance of IND to Initiate a Collaborative Phase II Basket Study with Iadademstat in R/R Patients with Neuroendocrine Carcinomas (NECs)

Oryzon Genomics S.A. announced that it expects to receive €20 million in funding from Nice & Green SA

Oryzon Genomics S.A. At Eha-2022: Iadademstat 42-Month Alice Data Demonstrate Robust Efficacy in Combination with Azacitidine in AML

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies